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Abstract Apoptosis-inducing factor mitochondrion-associated 1 (AIFM1), encoded by the
gene AIFM1, has roles in electron transport, apoptosis, ferredoxin metabolism, reactive
oxygen species generation, and immune system regulation. Here we describe a patient
with a novel AIFM1 variant presenting unusually early in life with mitochondrial disease,
rapid deterioration, and death. Autopsy, at the age of 4 mo, revealed features of
mitochondrial encephalopathy, myopathy, and involvement of peripheral nerves with
axonal degeneration. In addition, there was microvesicular steatosis in the liver, thymic
noninvolution, follicular bronchiolitis, and pulmonary arterial medial hypertrophy. This
report adds to the clinical and pathological spectrum of disease related to AIFM1
mutations and provides insights into the role of AIFM1 in cellular function.
INTRODUCTION
Mitochondrial disease can be due to genetic variants affecting the mitochondrial or nuclear
genome. Many well-characterized phenotypes of mitochondrial disease with encephalomy-
opathy are known, including mitochondrial encephalopathy with lactic acidosis and stroke-
like episodes (MELAS), Kearns–Sayre syndrome, and Leigh syndrome due to mutations in
genes that include SUCLA2, POLG, and VARS2 (Tang et al. 2011; Wong 2012; El-Hattab
and Scaglia 2013; Diodato et al. 2015).
Apoptosis-inducing factor mitochondrion-associated 1 (AIFM1) protein is known to have
oxidoreductase activity, with roles in electron transport, apoptosis, ferredoxin metabolism,
reactive oxygen species generation, and immune system regulation (Susin et al. 1999;
Miramar et al. 2001; Pospisilik et al. 2007). It was first identified as a flavoprotein that acts
as amitochondrial effector of apoptosis. Under healthy cellular conditions, AIFM1 is tethered
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to the inner mitochondrial matrix where it has a role in ATP production (Susin et al. 1999;
Vahsen et al. 2004). AIFM1, the gene encoding AIFM1, is located on the X Chromosome
at Xq26.1, and X-linked recessive diseases associated with AIFM1 variants have includedmi-
tochondrial encephalomyopathy, Cowchock syndrome (also known as X-linked Charcot–
Marie–Tooth disease-4), and X-linked deafness (Cowchock et al. 1985; Wang et al. 2006;
Ghezzi et al. 2010). In addition, a severe infantile encephalopathy and infantile motor neuron
disease has been recently reported (Diodato et al. 2015).
Here we describe a male infant with an X-linked sequence variant in AIFM1 and mito-
chondrial disease characterized by congenital lactic acidosis, intractable seizures, polyneu-
ropathy, and myopathy. Full postmortem examination, at the age of 4 mo, afforded
extensive pathologic characterization of this severe phenotype.
RESULTS
Clinical Presentation and Family History
The patient was born at 40 week (wk) gestation via spontaneous vaginal delivery to a 27-yr-
old G3P1 woman following an uneventful pregnancy. His birth weight was at the 82nd per-
centile for age. Family history included a healthy older sibling, previous maternal first trimes-
ter spontaneous abortion, maternal aunt with multiple sclerosis, and a paternal grandmother
with seizure disorder. His nursery course was unremarkable and he was discharged home
without incident.
At 2 days (d) of life, the patient presentedwith hypopnea and cyanosis. Venous blood gas
after intubation demonstrated significant metabolic acidosis with pH 6.67 and pCO2 of 46
mmHg (reference range: venous pH 7.31–7.41, pCO2 41–51). Glucose was elevated at
174 mg/dl (reference range: 52–100). Ampicillin, gentamicin, and acyclovir were started
for possible infectious etiology. Repeat venous blood gas demonstrated respiratory com-
pensation with pH 7.24, pCO2 24.5 mmHg, bicarbonate 10 mmol/l (reference range: 16–
21mmol/l). Blood gases normalized progressively on the day of admission, and serum bicar-
bonate levels increased to 15 mmol/l. Complete blood count including lymphocytes, serum
electrolytes, cerebrospinal fluid (CSF) cell counts, and CSF glucose at that time were essen-
tially normal for age. Physical exam did not reveal any malformations or dysmorphology.
Neurologic exam showed spontaneous movements of all four extremities with positive
suck and gag reflexes. Chest X-ray was without infiltrate or other abnormality.
The constellation of early-onset metabolic acidosis without hypoglycemia was concern-
ing for pyruvate dehydrogenase deficiency, so feeds were initially withheld and protein
content was slowly advanced in parenteral nutrition. Increasing glucose infusion rates did
not worsen the acidosis or lactate level. Biotin, carnitine, thiamine, and coenzyme Q10 sup-
plements were started on day 4. The patient also received sodium citrate/citric acid for his ac-
idosis.Nonmetabolic causes of acidosis such as cardiac shunt, renal bicarbonatewasting, and
pulmonary disease were ruled out on further testing. Infectious work up was also negative.
Metabolic and Neurologic Evaluation
Extensive metabolic evaluation was undertaken. Initial urine organic acids did demonstrate
marked increase in lactic acid, pyruvic acid, fumaric acid, and malic acid; subsequent
samples demonstrated increases in lactic and pyruvic acid suggestive of a mitochondrial dis-
order. There were a large amount of ketones and a small dicarboxylic aciduria noted, attrib-
uted to the ketosis. Plasma amino acids had transient increases in several branched chain
amino acid metabolites, with subsequent testing notable only for being consistent with
low protein intake. Urine organic acid profile had a small elevation of propionylglycine
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initially with subsequent testing consistent with carnitine supplementation. Other metabolic
testing included normal results for ammonia, pyruvate, free and total carnitine, β-hydroxy-
butyrate, acetoacetate, creatine kinase, urine ketones, urine-reducing substances, urine
acylglycines, CSF amino acids, and CSF neurotransmitters. 5-Methyltetrahydrofolate, tetra-
hydrobiopterin, and neopterin profiles were normal. CSF lactate (6 mmol/l, reference range:
0.9–2.5 mmol/l) and pyruvate were elevated. Skin fibroblasts demonstrated normal activity
of the pyruvate dehydrogenase complex.
MRI/MRA on the second day of life demonstrated underopercularization of the Sylvian
fissures and prominence of the bifrontal and bitemporal extra-axial spaces. There was small
subdural bleeding over the cerebellum, whichwas consideredbirth-related.Myelination pat-
ternwas normal for the patient’s age. Electroencephalogram (EEG) on the third dayof lifewas
suggestive of a moderate diffuse encephalopathy of nonspecific etiology but no electro-
graphic or electro-clinical seizures, and subsequent EEG reading on the fourth day of life
was within normal limits for age. Electromyography at 4 wk of age and again at 3 mo, dem-
onstrated moderately severe axonal and sensorimotor polyneuropathy. Ophthalmologic
evaluation at 8 wk of agewas normal without optic nerve anomaly or pigmentary retinopathy.
Isoelectric focusing was negative for congenital disorders of glycosylation.
Clinical Genetic Evaluation
Mitochondrial genome scan had a common synonymous single-nucleotide variant (m.14121
C>T), and no deletions were identified. Gene sequencing detected no pathogenic SURF1 or
SCO1 variants, and although multiple variants were found in COX10, POLG, and SCO2,
none were known to be pathogenic. Chromosomal microarray revealed a 1.3-Mb paternally
inherited duplication at 16q23.3.
Subsequent Clinical Course
After initial metabolic testing results were nondiagnostic, formula feedings were reintro-
duced without difficulty. Cardiac evaluation was normal including normal echocardiograms
at 6 d and 3 months of age. The patient had a second episode of respiratory failure in the
setting of severe acidosis at 3 wk of age, requiring intubation for 1 d. His lowest bicarbonate
during this second episode was 6 mmol/l (reference: 17–25 mmol/l), and highest lactate was
21.4 mmol/l (reference range: 0.5–2.2 mmol/l). Dichloroacetate was initiated at 1 mo of age
as an investigational drug for congenital lactic acidosis. Following this second episode, head
computed tomography (CT) showed new hypodensities in the anteromedial thalami bilater-
ally. Repeat magnetic resonance imaging (MRI) demonstrated T2 hyperintensity in the bilat-
eral anteromedial thalami with increased signal on diffusion-weighted images, in addition to
the bifrontal and bitemporal extra-axial space prominence. After 2 mo in the neonatal inten-
sive care unit (NICU), the patient was stable on room air and was discharged home.
One week after discharge, the patient was readmitted at 2.5 mo of life following a series
of cyanotic events associatedwith seizures. On admission he had lactate levels at his baseline
of 3–5 mmol/l, and examination was notable for axial and appendicular hypotonia. He was
started on phenobarbital for management of seizures. EEG indicated diffuse encephalopa-
thy, frequent left occipital sharp waves, right occipital sharp waves, and no electrographic
seizures. Modified barium swallow study demonstrated silent aspiration of thin liquids and
oromotor discoordination with thickened feeds. Repeat MRI demonstrated cerebral atrophy
in addition to previous findings. After 1 wk he was again stable on room air, taking thickened
feeds by mouth without difficulty and was discharged home.
The patient was again readmitted 2 d after discharge for an episode of lethargy and
cyanosis. EEG at this time demonstrated seizures arising from the right occipital and left pari-
eto-occipital regions, and the absence of a posterior dominant rhythm and slowing in the
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posterior quadrants consistent with diffuse encephalopathy. Repeat brainMRI demonstrated
new restricted diffusion in the bilateral basal ganglia, brainstem, and bilateral occipital lobes
(Fig. 1). There was abnormal T2 signal intensity within the head and body of the caudate nu-
clei bilaterally and the bilateral anterior putamina (Fig. 1A). A new inverted lactate doublet at
1.33 ppm on single-voxel MR spectroscopy (echo time 144 msec) was observed within a
voxel placed over the left basal ganglia (Fig. 1B). Muscle biopsy during this admission dem-
onstrated decreased activity of electron transport chain complex I and IV, with normal activity
of complexes II and III.
During this admission, the patient could not be extubated because of hypoventilation.
He received phenobarbital and gabapentin. The gabapentin was discontinued after a
week because of possible gastrointestinal side effects. He had progressive abdominal disten-
sion and was unable to tolerate enteral feeds, which was ultimately attributed to progressive
mitochondrial dysfunction. There was no significant lactate elevation during this hospitaliza-
tion. Dichloroacetate was discontinued on admission for concern for worsening neuropathy
based on nerve conduction study. Given his poor neurologic prognosis, care was redirected,
and he died at the age of 4 mo.
Pathology
Central and Peripheral Nervous System
Grossly, the brain was of generally normal configuration, weighing 570 g (expected for age:
700 g), and the posterior fossa contents weighed 61 g (10th percentile). The gyral pattern
appeared coarse, and sulci appeared mildly widened. The superior temporal gyrus was
thin bilaterally (Fig. 2A) and the corpus callosum and fornix were thin (Fig. 2B). The internal
capsule was firm, suggesting gliosis. The occipital cortices appeared thin, and the ventricular
system was mildly enlarged, consistent with ex vacuo atrophy.
Microscopically, the frontal and parietal cortices showed a reasonable population of well-
differentiated neurons and normal lamination, although therewas somepatchy neuronal loss
and subtle vacuolation of upper cortical layers II–III. In contrast, the occipital cortex showed
profound neuronal loss (Fig. 2C), gliosis, slight prominence of blood vessels (Fig. 2D), and
Figure 1. Magnetic resonance imaging (MRI) study demonstrates progression of mitochondrial disease. (A)
Restricted diffusion in the basal ganglia, brainstem, and occipital lobe (white arrows) were noted, as well as
abnormal T2 signal intensity in the bilateral caudate heads and anterior putamina (arrowheads). Extra-axial
spaces were pronounced anteriorly (stars). (B) Inverted lactate doublet is seen at 1.33 ppm on MRI spec-
troscopy from a voxel placed over the basal ganglia.
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vacuolization of the full thickness of the neocortex with subpial and white matter gliosis. In
the hippocampal formation the dentate gyrus and pyramidal cell layer were cytoarchitectur-
ally normally formed. However, the pyramidal cell layer (CA1) was devastated, with marked
neuronal loss, vacuolization (Fig. 2E), and scattered hypereosinophilic cells. The cerebellar
cortex had the normal layers and a residual external granular layer appropriate for age.
However, there was significant patchy loss of Purkinje cells and Bergmann gliosis in the cer-
ebellar hemispheres; these changes became severe, associated with substantial atrophy, in
the vermis (Fig. 2F). Glial fibrillary acid protein (GFAP) immunocytochemistry highlighted
moderate reactive gliosis in both cortex and white matter. The dentate nucleus was severely
Figure 2. Central nervous system pathological findings on autopsy. (A) The superior temporal gyrus was thin
bilaterally (yellow arrowhead). Scale bar, 1 cm. (B) On coronal cut sections, the corpus callosum and fornix were
thin (red arrowhead). The ventricular system was mildly enlarged, indicating ex vacuo atrophy. Scale bar,1 cm.
(C ) The left occipital cerebral cortex (LFB/CV, 10×) showed spongy neuropil, with almost complete loss of neu-
rons, whereas the underlying white matter was hypomyelinated because of both overlying cortical damage
and the patient’s young age. (D) Left occipital cerebral cortex (CD34, 10×) showing the prominence and pro-
liferation of small vessels and capillaries in the damaged cerebral cortex. (E) Hippocampal pyramidal cell layer
hematoxylin and eosin (H&E) 10×, showing the marked loss of CA1 pyramidal neurons, and the vacuolation of
this layer. (F ) Cerebellar cortex, H&E 10×, showing the depletion of the granular cell layer and widened
Virchow–Robin spaces, indicating parenchymal atrophy. Thewhitematter is gliotic (confirmed on glial fibrillary
acid protein [GFAP] immunocytochemistry, not shown).
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depleted of neurons, and there was vacuolation in the caudate and putamen that was less
extensive compared with the cortex.
A sample of peripheral nerve showed thin myelination of large axons, appropriate for age,
and scattered axonal degeneration, with debris-filled profiles and “myelin ovoids” (Fig. 3A,B).
Muscle Pathology
Muscle biopsy of the left quadriceps at 8 wk of age demonstrated pyruvate dehydrogenase
complex in muscle showed high normal activity. Hematoxylin and eosin (H&E) stain demon-
strated mild variability in fiber size. There was no inflammation, internalized nuclei, degen-
erating or necrotic fibers, myophagocytosis, or nuclear bags. Trichrome stain revealed
normal connective tissue and myofibrillar structure. Periodic acid–Schiff (PAS) stain revealed
normal content and appearance of glycogen, and oil red-O stain demonstrated normal
content of lipid. Nicotinamide adenine dinucleotide (NADH) histochemical stain revealed
the usual finely stippled staining pattern and an unremarkable intermyofibrillar network.
ATPase histochemical stains at pH 4.3 and 9.4 showed good distinction of fiber types and
a normal distribution of fiber types in a checkerboard pattern. Staining for cytochrome oxi-
dase (COX) was within normal limits. Electron microscopy demonstrated mitochondria that
were irregular and bizarrely shaped without inclusions, numerous atrophic fibers, moderate
myofiber disarray, and scattered fibers with subsarcolemmal accumulations of glycogen
and slightly prominent lipid stores. A mitochondrion with concentric cristae was also noted
(Fig. 3C).
Figure 3. Peripheral neuromuscular pathological findings. (A) Peripheral nerve, cross section plastic semithin
section, toluidine blue, 100× showing generally thin myelin sheaths, likely appropriate for age, and scattered
debris-filled profiles of degenerating axons. (B) Peripheral nerve, longitudinal section plastic semithin section,
toluidine blue, 100× showing the fusiform profile of a degenerating axon. (C ) Electron microscopy of quadri-
cepsmuscle demonstrating large, irregularly shapedmitochondria, including onewith concentric cisternae (ar-
row). (D) Quadriceps muscle biopsy (antemortem), Gomori trichrome 100×, showing largely intact fibers with
coarse stippling and scattered fibers with subsarcolemmal aggregates corresponding to mitochondria.
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Psoas muscle from the autopsy showed increased subsarcolemmal material. A trichrome
stain showed a distinct subsarcolemmal accumulation of red-purple material, occasionally
approaching frank “ragged red fibers,” in the majority of fibers. The toluidine blue semithin
sections showed variation in fiber diameter and marked fine cytoplasmic vacuolization, the
latter possibly representing postmortem artifact (Fig. 3D). The heart was normal on gross
and microscopic examination.
Other Autopsy Findings
Diffuse microvesicular steatosis was seen in the liver (Fig. 4A). The lungs showed follicular
bronchiolitis, most prominent in the right upper lobe (Fig. 4B); in situ hybridization for
Epstein–Barr virus early antigen was negative. In addition, small- and medium-sized pulmo-
nary arteries showed moderate concentric medial hypertrophy. The thymus weighed 39 g
and showed a lack of tingible-body macrophages. Hydroceles were present bilaterally,
more prominent on the right side (Fig. 4C). The seminal vesicle was distendedwith abundant
globular eosinophilic secretions.
Genomic Analyses
Whole-exome sequencing was performed on genomic DNA from the proband and his moth-
er. The identified variants in the proband were filtered to include rare variants (mean allele
frequency < 0.01) using publicly available Exome Variant Server (http://exac.broadinstitute.
org) and 1000 Genomes (http://www.1000genomes.org) databases. Sequencing statistics
are available in Table 1. A total of 431 variants were included after the above filtering criteria.
Figure 4. Nonneuromuscular findings on autopsy. (A) Diffuse microvesicular steatosis, characterized by small
cytoplasmic vesicles in the majority of hepatocytes (H&E, original magnification 200×). (B) Follicular bronchio-
litis, prominent in the right upper lobe; aggregates of lymphoid cells organized into follicles cuff small airways
(H&E, original magnification 100×). (C ) Right (6-cm) and left (3-cm) hydroceles.
Table 1. Sequencing statistics for whole-exome analysis
Family
members
Total
reads Mapped reads
Reads on
target
Average
coverage (×)
Target region at 20×
plus coverage
Proband 86,633,632 83,531,396
(96.4%)
51,179,686
(61.3%)
103 95.1%
Mother 73,649,659 67,263,058
(91.3%)
42,678,410
(63.5%)
89 94.9%
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The variants were first screened for mitochondrial genes, and only one variant in a known
mitochondrial gene was identified. The variant was a missense change in AIFM1, an X-linked
recessive gene (Table 2). Those 431 mutations were further evaluated for recessive (auto-
somal/X-linked) changes, and seven genes, including AIFM1, satisfied that criteria. On
Sanger sequencing, the proband was confirmed to have a sequence variant in AIFM1 (Fig.
5A), hg19, X:129267300T>C, c.1436A>G, which results in the amino acid change p.
Gln479Arg in exon 13. This variant is not present in the ExAC database and was predicted
to be pathogenic by MutationTaster, PolyPhen-2, and SIFT. The altered residue is very
well conserved across various vertebrate species (Fig. 5B). The crystal structure of human
AIFM1 (PDB code: 4BUR) indicates two NAD and one flavin adenine dinucleotide (FAD)mol-
ecules bind to AIFM1. The residue Gln479 is located at a loop forming the binding pocket of
Table 2. AIFM1 variant summary
Gene Chromosome
HGVS DNA
reference
HGVS
protein
reference
Variant
type
Predicted
effect dbSNP Genotype
AIFM1 X NM_004208.
3:1436:A
Gln479 Substitution Gln>Arg 1057516211 X-linked
recessive
Information regarding observed X-linked recessive variant in AIFM1.
HGVS, Human Genome Variation Society; dbSNP, Database for Short Genetic Variations.
Figure 5. Genetic variation in AIFM1 in affected patient. (A) Sanger sequencing results for affected region of
AIFM1. The A→G mutation at position 1436 is present in the proband (top row) but not the parents (bottom
two rows). (B) Alignment of affected amino acid across vertebrates with residue Gln479 colored in red.
Nonconserved amino acids are in blue text. (C ) Location of Gln479 variation. One AIFM1 binds to two NAD
(colored in cyan) and one FAD (colored in orange). Residue Gln479 (colored in red) is near the binding of
the FAD and one NAD. Its amino group interacts with the hydroxyl group of residue Asp443 electrostatically.
(D) The NAD and FAD molecules are shown in Sphere. The mutation Gln479Arg does not change the charge
status of this residue, but extends the length of the side chain of Gln479, whichmight disrupt the bindingpock-
et of FAD and/or NAD. This change might affect the binding capability of AIFM1 to FAD and/or NAD.
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NAD and FAD.Moreover, Gln479 forms a salt bridgewith Asp443, which is located at anoth-
er NAD and FAD binding loop. The salt bridge links two substrate binding loops, and likely
coordinates the dynamic of two loops for substrate binding and enzymatic activities.
Strikingly, both Gln479 and Asp443 are not close to other AIFM1 pathogenic mutations,
which are around the binding sites of NAD and FAD (Sevrioukova 2016). Mutating Gln479
to Arg479 increases the side chain volume and positive charges significantly. Subsequently
this change might alter protein stability or affect the binding capability of AIFM1 to FAD
and/or NAD (Fig. 5C,D; Ferreira et al. 2014).
DISCUSSION
Here we report a case of severe, fatal, early-onset mitochondrial encephalomyopathy in an
infant with a novel variant in AIFM1. Previous reports have associated AIFM1mutations with
abnormalities of the nervous system including progressive mitochondrial encephalomyop-
athy (Ghezzi et al. 2010), X-linked Cowchock syndrome (Rinaldi et al. 2012; Zimon´ et al.
2012), slowly progressive mitochondrial disease (Ardissone et al. 2015), auditory neuropathy
spectrum disorder (Zong et al. 2015), X-linked congenital ptosis and intellectual disability
(Møller et al. 2014), and prenatal ventriculomegaly without lactic acidosis (Table 3; Berger
et al. 2011). The Harlequin mouse, a mouse with mutation in Aifm1 that affects the redox
and DNA binding activities of AIFM1, is associated with decreased activity of complex I/
III, neuronal degradation and muscle atrophy (Klein et al. 2002; Joza et al. 2005).
There have been several genotype–phenotype correlations made in previous case re-
ports which both point toward the multiple roles of AIFM1 in cell regulation as well as the
pathophysiology of related human conditions. AIFM1mutations that impair oxidative phos-
phorylation have presented within the first year of life with severe mitochondrial encephalo-
myopathy. Alternatively, mutations that affect the redox properties of AIF lead to increased
cell death and have been associated with Cowchock syndrome. Most similarly to our case,
there were two related male infants with severe mitochondrial encephalomyopathy who
had both defects in oxidative phosphorylation as well as increased apoptosis (Ghezzi et al.
2010). Clearly there are also tissue-specific effects, asmuscle hadmore significant respiratory
chain dysfunction than skin fibroblasts (Ghezzi et al. 2010; Berger et al. 2011).
There were several notable neuromuscular system findings in our infant on histopatho-
logical examination. Brain tissue damage was found to be bilaterally symmetric, and the ex-
tent of capillary proliferation and occipital white matter injury was consistent with that found
Table 3. Summary of previously identified human AIFM1 variants
Variant Phenotype Reference
Arg201del Severe mitochondrial encephalomyopathy Ghezzi et al. 2010
Gly338Glu Early-onset mitochondrial encephalomyopathy Diodato et al. 2015
Glu493Val Early-onset axonal sensorimotor neuropathy Rinaldi et al. 2012
Gly262Ser Slowly progressive mitochondrial encephalomyopathy Ardissone et al. 2015
Gly308Glu Early-onset encephalomyopathy Berger et al. 2011
Leu344Phe Auditory neuropathy Zong et al. 2015
Thr260Ala Auditory neuropathy Zong et al. 2015
Arg422Trp Auditory neuropathy Zong et al. 2015
Arg422Gln Auditory neuropathy Zong et al. 2015
Arg451Gln Auditory neuropathy Zong et al. 2015
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in other forms of mitochondrial encephalopathy such as Leigh syndrome. Although periph-
eral neuropathy is not uncommon in mitochondrial disorders, it could also indicate a further
role for AIFM1within the nervous system. Alternative explanations for the peripheral neurop-
athy could include an adverse effect of dichloroacetate. Skeletal muscle findings demon-
strated expected findings in mitochondrial disease, including structural abnormalities of
the mitochondria. The subsarcolemmal accumulations of glycogen and slightly prominent
lipid stores that were present at autopsy, but not in the initial sample from 8 wk of age,
were also consistent with progressive mitochondrial dysfunction.
Significant findings were present throughout general examination that could relate
directly to AIFM1mutation. The patient’s thymus gland was markedly larger than expected.
The postmortem observed weight of 39 g was substantially larger than the 9.5-g expected
weight for an infant of his length (Coppoletta and Wolbach 1933), despite the history of
neonatal stress, which typically results in a smaller-than-expected thymus gland. The tin-
gible-body macrophages that are typically associated with apoptosis and thymic regression
were lacking. It is interesting to speculate whether the abnormal AIFM1 interfered with the
normal apoptotic regression of the thymic gland. The hepatic finding of microvesicular stea-
tosis is a known consequence of disruption or deficiency of the mitochondrial β-oxidation
process (Fromenty and Pessayre 1997), and in the setting of abnormal AIFM1 may be due
to direct impairment of oxidative phosphorylation in hepatocytes.
Two pulmonary findings were of interest in this case. Follicular bronchiolitis in the pe-
diatric population is often seen in the setting of genetic immune dysregulation, and its oc-
currence in conjunction with AIFM1 mutation in this patient is therefore striking. It is
possible that the proliferation of bronchus-associated lymphoid tissue might be driven
by factors that interact with AIFM1. It is interesting to note that caspase, which may be
modulated by AIFM1, is elevated in bronchoalveolar lavage fluid in children, where it
has been correlated with bronchiolitis severity (Laham et al. 2010; Mehta et al. 2014).
We thus provide preliminary evidence that genetic variants in AIFM1 may be a member
of the growing list of heritable mutations contributing to pediatric follicular bronchitis/bron-
chiolitis. It is also tempting to relate the patient’s pulmonary arterial medial hypertrophy to
the deficiency of AIFM1. This pulmonary arterial hypertensive remodeling was likely sec-
ondary to critical illness, although AIFM1 could increase the likelihood of developing sec-
ondary pulmonary hypertension via interaction with the aldosterone axis (Xiao et al. 2014),
which in turn is known to modulate pulmonary arterial hypertensive changes (Maron and
Leopold 2015).
To summarize, our report is the first to characterize detailed autopsy findings in lactic
acidosis and early-onset, rapidly progressive epilepsy of infancy associated with AIFM1mu-
tation. The findings expand the clinical and pathologic spectra of disease related to AIFM1
abnormality, and provide further insights into the broad relevance that AIFM1 has in human
disease.
METHODS
Genomic Analysis
Next-Generation Exome Sequencing
Whole-exome sequencing was completed for the patient and mother. All studies were
completed according to approval of the Institutional Review Board of Boston Children’s
Hospital. Total genomic DNA was extracted from peripheral blood lymphocytes using
QIAmp DNA Mini Kit (QIAGEN). DNA from the proband and mother was sent for whole-
exome sequencing (WES) at Claritas Genomics. Samples were prepared as an Illumina
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sequencing library and enriched for exomic sequences using the Agilent V5 Sureselect kit.
The captured libraries were sequenced using Illumina HiSeq 2000 Sequencers at Lab Corp.
Data Analysis
FASTQs generated from exome sequencing were filtered, aligned, and variants were filtered
and annotated by Codified Genomics (proprietary algorithm).
Structural Modeling
The structural modeling of AIFM1Gln479Arg and the structural elucidation of both wild-type
and mutant AIFM1 were generated using PyMOL (The PyMOL Molecular Graphics System,
Version 1.8 Schrödinger, LLC.).
Clinical Record Review
Medical data were abstracted from electronic records. Growth parameters were calculated
using the Centers for Disease Control and Prevention (CDC) data.
Pathologic Examination
Muscle Biopsy
An antemortem open biopsy of quadriceps muscle and a postmortem sampling of psoas
muscle were obtained. Muscle was snap frozen in isopentane, cooled in liquid nitrogen,
and mounted in optimal cutting temperature (OCT) compound. Six micron sections were
cut and mounted onto microscope slides. Gomori trichrome, NADH, ATPase pH 4.6, and
COX staining were carried out according to standard protocols. Microscopic sections includ-
ing H&E, and selected section stained with luxol fast blue (LFB)/Nissl, Bielschowski silver
stain, and immunostains (GFAP, NeuN, Factor VIII, neurofilament protein, SMI 31) were
examined. A portion of muscle was fixed in gluteraldehyde, embedded in plastic; semithin
sections were stained with toluidine blue, and ultrastructural examination was conducted.
Postmortem Examination
Parents gave consent for a full, unrestricted autopsy. External examination was conducted.
Evisceration was conducted through a standard Y-shaped thoracoabdominal incision, and
the brain was removed via the calvarium. Organs were examined and dissected in the fresh
state, except for the brain, which was fixed before dissection. Histologic sections were fixed
in formalin, embedded in paraffin, and sectioned at 5 microns for microscopic examination.
Peripheral nerve and skeletal muscle were processed for electron microscopic examination.
ADDITIONAL INFORMATION
Data Deposition and Access
Genetic variant data was submitted to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar) under
accession number SCV000484975. Raw data were not deposited because of lack of patient
consent.
Ethics Statement
Research protocol was approved by the Institutional Review Board at Boston Children’s
Hospital. All procedures followed were in accordance with the ethical standards of the re-
sponsible committee on human experimentation (institutional and national) and with the
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Helsinki Declaration of 1975, as revised in 2000. Oral and written consent for study enroll-
ment and publication was obtained from the subject’s parents.
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